Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Error occurred: cannot get document summary
Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.
Shukuya T, Takahashi T, Harada H, Akamatsu H, Sakaguchi C, Imai H, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi K, Yamamoto N.
Anticancer Res. 2012 Feb;32(2):675-80.
Related citations
Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer.
Aoki T, Igawa S, Furuya N, Katagiri M, Hisata J, Tajiri S, Hayama N, Mineshita M, Urano T, Miyazawa T, Masuda N, Abe T.
Anticancer Res. 2012 Feb;32(2):601-8.
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.
Richardson F, Young GD, Sennello R, Wolf J, Argast GM, Mercado P, Davies A, Epstein DM, Wacker B.
Anticancer Res. 2012 Feb;32(2):537-52.
Caveolin-1 attenuates hydrogen peroxide-induced oxidative damage to lung carcinoma cells.
Suchaoin W, Chanvorachote P.
Anticancer Res. 2012 Feb;32(2):483-90.
Vitamin D: potential in the prevention and treatment of lung cancer.
Norton R, O'Connell MA.
Anticancer Res. 2012 Jan;32(1):211-21. Review.
A population-based study of the pattern of terminal care and hospital death in patients with non-small cell lung cancer.
Nieder C, Tollåli T, Norum J, Pawinski A, Bremnes RM.
Anticancer Res. 2012 Jan;32(1):189-94.
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
Kosmidis PA, Syrigos K, Kalofonos HP, Dimopoulos MA, Skarlos D, Pavlidis N, Boukovinas I, Bafaloukos D, Pectasides D, Bacoyiannis C, Fountzilas G.
Anticancer Res. 2012 Jan;32(1):175-81.
Clinical application of MAGE A1-6 RT-nested PCR for diagnosis of lung cancer invisible by bronchoscopy.
Shin KC, Choi EY, Chung JH, Jeon C, Lee KH.
Anticancer Res. 2012 Jan;32(1):163-7.
The hedgehog pathway inhibitor GDC-0449 alters intracellular Ca2+ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells.
Tian F, Schrödl K, Kiefl R, Huber RM, Bergner A.
Anticancer Res. 2012 Jan;32(1):89-94.
The prognostic significance of HER2 overexpression in non-small cell lung cancer.
Takenaka M, Hanagiri T, Shinohara S, Kuwata T, Chikaishi Y, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, Nakagawa M, Uramoto H, So T, Tanaka F.
Anticancer Res. 2011 Dec;31(12):4631-6.
Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Kobayashi M, Sonobe M, Takahashi T, Yoshizawa A, Ishikawa M, Kikuchi R, Okubo K, Huang CL, Date H.
Anticancer Res. 2011 Dec;31(12):4619-23.
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.
Inomata M, Shukuya T, Takahashi T, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Murakami H, Harada H, Endo M, Yamamoto N.
Anticancer Res. 2011 Dec;31(12):4519-23.
The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer.
Herpel E, Jensen K, Muley T, Warth A, Schnabel PA, Meister M, Herth FJ, Dienemann H, Thomas M, Gottschling S.
Anticancer Res. 2011 Dec;31(12):4491-500.
Prognostic significance of TIMP-1 in non-small cell lung cancer.
Pesta M, Kulda V, Kucera R, Pesek M, Vrzalova J, Liska V, Pecen L, Treska V, Safranek J, Prazakova M, Vycital O, Bruha J, Holubec L, Topolcan O.
Anticancer Res. 2011 Nov;31(11):4031-8.
Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F, Marino F, Fanti G, Chiara GB, Basso SM.
Anticancer Res. 2011 Nov;31(11):3879-81.
Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Oriuchi N, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N.
Anticancer Res. 2011 Nov;31(11):3775-82.
Targeting cyclin D1 in non-small cell lung cancer and mesothelioma cells by antisense oligonucleotides.
Saini SS, Klein MA.
Anticancer Res. 2011 Nov;31(11):3683-90.
Vitamin D in colorectal, breast, prostate and lung cancer: a pilot study.
Pazdiora P, Svobodova S, Fuchsova R, Kucera R, Prazakova M, Vrzalova J, Narsanska A, Strakova M, Treskova I, Pecen L, Treska V, Holubec L Jr, Pesek M, Finek J, Topolcan O.
Anticancer Res. 2011 Oct;31(10):3619-21.
Interaction of CCND1 genotype and smoking habit in Taiwan lung cancer patients.
Hsia TC, Liu CJ, Lin CH, Chang WS, Chu CC, Hang LW, Lee HZ, Lo WC, Bau DT.
Anticancer Res. 2011 Oct;31(10):3601-5.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on